| 1. KEYTRUDA is a registered trademark of Merck & Co., Inc. KYMRIAH is a registered trademark of Novartis Pharmaceuticals Corporation.
Grab Sources Here: CTXR Presentation. -----
5 Critical Potential Catalysts To Consider - Key (Nasdaq: CTXR) Details
There are 5 potential catalysts that could attract attention to CTXR and should be looked at understood closely.
Here's what to know:
#1. Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025.
The anticipated commercial launch of LYMPHIR™, an FDA-approved immunotherapy for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), represents a significant milestone for Citius Pharmaceuticals, the parent company of Citius Oncology.
This transition will position Citius Pharmaceuticals as a fully integrated commercial-stage organization, highlighting its capacity to advance therapies from development to market.
Comprehensive preparations—including completed commercial-scale manufacturing, robust supply chain agreements, and engagement with top-tier distribution partners—ensure that LYMPHIR will be accessible to patients across the United States, both in major cancer centers and community settings.
Citius Oncology’s collaboration with key opinion leaders, patient advocacy groups, and the broader clinical community has informed a patient-centered approach to the launch, while targeted marketing strategies and educational resources are set to support healthcare providers and patients.
The inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines and the assignment of a permanent J-code facilitate efficient reimbursement and coverage, further supporting broad adoption.
For Citius Pharmaceuticals, LYMPHIR’s launch will not only expand its oncology portfolio but also strengthen its reputation as an innovative force in specialty pharmaceuticals.
This milestone enhances operational capabilities, opens new partnership opp's, and sets the stage for future growth and development within the oncology sector.
#2. A Limited Float Could Amplify Market Volatility Potential.
Market watchers may note that CTXR’s float is on the fairly low side.
Based on data from Yahoo Finance, the company’s float is approximately 15.21Mn shares.
Why does this matter? A low float can often translate to greater volatility potential.
With great volatility potential comes the need for watching CTXR with a very close eye.
#3. Empowering Precision Growth Through Strategic AI Integration For CTXR.
Citius Pharmaceuticals, Inc. is poised for a strong U.S. launch of its FDA-approved immunotherapy LYMPHIR™ for cutaneous T-cell lymphoma, supported by advanced AI integration through Verix’s Tovana platform.
This collaboration enhances commercial strategy, enabling targeted healthcare provider engagement and data-driven market execution.
Leveraging machine learning and real-world analytics, Citius aims to maximize market penetration, improve precision marketing, and sustain long-term value creation.
The initiative underscores Citius Pharma’s innovation, efficiency, and commitment to expanding access for patients needing breakthrough oncology treatments.
#4. CTXR Strengthens Nationwide Access Through Strategic McKesson Partnership (Company Aims For Robust National Supply Chain).
Citius Pharmaceuticals, Inc. announced that its oncology subsidiary finalized a U.S. distribution agreement with McKesson Corporation for LYMPHIR™, its FDA-approved immunotherapy for cutaneous T-cell lymphoma.
With McKesson joining the network, Citius now partners with all three major U.S. pharmaceutical distributors, completing a robust national supply chain.
This milestone ensures broad, dependable access for physicians and patients ahead of LYMPHIR’s planned fourth-quarter 2025 launch.
The collaboration underscores Citius Pharma’s operational strength, commitment to patient access, and readiness for a successful commercial rollout in the oncology market.
#5. An Analyst Target Suggests Triple-Digit Potential Upside.
According to reports from Benzinga and TipRanks, D. Boral Capital analyst Jason Kolbert has set a $6 target on CTXR.
From Monday's closing valuation, this target suggests over 400% upside potential.
Could this suggest that CTXR is undervalued from current chart levels? -----
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has overtaken the top spot on my watchlist as coverage is officially underway.
Be on the lookout for updates coming soon.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 11/24/2025 and ending on 11/25/2025 to publicly disseminate information about (CTXR:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid six thousand USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid twenty five thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (CTXR:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ctxr-rqeje/#details | 
